First Tracks Biotherapeutics Inc
NASDAQ:TRAXBiotechnology
-$0.89 today
- Market cap
- $1.87B
- Beta
- 0.00
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$2.81
Volume 0.75M
Average 0.43M
TRAX Total Debt
Short-term and long-term borrowings combined.
First Tracks Biotherapeutics IncNASDAQ: TRAX
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt remains negative
Q1 FY2026 total debt was $0, compared with $0 a year earlier.
Context
- Total debt amounted to 0.0% of total assets at the end of Q1 FY2026.
- Total debt increased in 0 of the last 2 fiscal years.
- FY2025 was the lowest annual figure in the 3 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 14.11M USD
- Year-over-year change
- -12.0%
- 2-year CAGR
- -11.0%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.11M | -12.0% |
| FY2024 | 2024-12-31 | 16.04M | -10.0% |
| FY2023 | 2023-12-31 | 17.81M | — |
Total Debt vs competitors
How TRAX compares with its peers on the latest reported figures
- TRAX's Mar 2026 total debt of $0 is the 9th highest of the 10 companies compared; the peer median is $1.99M.
- Total debt amounts to 0.0% of total assets for TRAX, versus a peer median of 1.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $277.36M | +1680.8% | -10.1% | 84.1% | |
| Mar 2026 | $100.8M | +33.3% | +544.7% | 25.2% | |
| Jun 2026 | $5.13M | -20.0% | +0.1% | 2.2% | |
| Jun 2026 | $4.33M | — | — | 3.4% | |
| Mar 2026 | $1.99M | -20.1% | +45.7% | 1.0% | |
| Mar 2026 | $555K | -36.9% | -4.9% | 0.4% | |
CLYMClimb Bio, Inc. | Mar 2026 | $479K | +1.1% | +4.1% | 0.3% |
| Mar 2026 | $421K | -56.8% | -24.1% | 0.2% | |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $0 | — | — | 0.0% |
| Sep 2026 | $0 | — | -61.1% | 0.0% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding TRAX) | $1.99M | -20.0% | -2.4% | 1.0% | |
Competitors are the stored peer set for TRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
First Tracks Biotherapeutics Inc
NASDAQ:TRAX
Intrinsic Alpha fair value
Locked
Current Price
$44.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.